ArticleClinical and experimental vaccine research2025
Cholera toxin B subunit fusion enhances the immunogenicity of the H5 stem domain against the H5N2 avian influenza virus.
Article in Clinical and experimental vaccine research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The development of a universal avian influenza vaccine remains a critical issue for both the global public health and poultry industries. The hemagglutinin (H) stem/stalk region of highly pathogenic avian influenza viruses (HPAIVs) is capable of inducing broadly neutralizing antibodies but is limited by its poor immunogenicity. Materials and Methods: To increase the immunogenicity of the stem domain, we engineered a recombinant fusion construct consisting of the stem domain of the H5 subtype and the nontoxic cholera toxin B subunit (CTB), a well-characterized mucosal adjuvant and immunomodulator. C57BL/6 mice were immunized intraperitoneally with the CTB-H5 stem fusion protein. Humoral immune responses and virus-neutralizing activities were subsequently assessed. Results: Mice immunized with CTB-H5 stem fusion protein developed significantly higher serum immunoglobulin G titers and increased binding affinity to the native trimeric H5 antigen. Sera from the CTB-H5 stem group demonstrated enhanced virus-neutralizing activity in plaque reduction assays against the H5N2 virus. These results suggest that CTB fusion significantly enhances the immunogenicity and protective potential of the conserved H5 stem domain against the H5N2 virus. Conclusion: These findings support the use of CTB as an effective adjuvant platform for the development of stem-based influenza vaccines targeting HPAIVs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.